Although we do not know which of the antigen targets in the vaccine (NP, M1, or M2) that contributes to the observed NK cell activation, human anti-NP IgG antibodies induced by natural or experimental infection have been shown to activate NK cells by FcγRIIIa engagement [18]. This evidence concerns the gene FCGR3A and infection.